Full Report

Industry — Understand the Playing Field

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

1. Industry in One Page

SKC does not sit in one industry — it sits in three distinct material industries that share a customer base of Korean and Asian electronics producers but have unrelated economics: (1) battery copper foil for lithium-ion EV/ESS cells, sold to cell-makers like Samsung SDI, LG Energy Solution and SK On under multi-year volume contracts; (2) semiconductor materials — test sockets at ISC, glass substrates at Absolics, and historically CMP pads/blank masks — sold to fabs (Samsung, SK hynix), OSAT testers and AI accelerator vendors (NVIDIA, Broadcom, Google); and (3) commodity petrochemicals — propylene oxide, propylene glycol and styrene monomer at SK picglobal — sold by the tonne against Asian spreads. The newcomer's mistake is to treat SKC as a single "specialty chemicals" name; in 2025 the chemicals segment was the largest by revenue ($753M) but the most cyclical, while the smallest segment — semi materials at $152M — was the only one earning operating profit. The investment story is therefore not about one industry cycle; it is about rotating mix away from oversupplied commodity foil and PG/PO toward AI-leveraged semi materials, with the timing of that rotation set by external industry forces, not internal management will.

Takeaway: The biggest revenue contributor is the worst earner; the smallest is the only earner. The industry mix problem is the investment problem.

2. How This Industry Makes Money

Each of SKC's three industries earns money in a different way, and the wrong mental model destroys valuation judgment. A reader who thinks of all three as "specialty chemicals" will overpay for the commodity segment and underpay for the test-socket business.

Reading the table. The key concept is the processing fee (also called "tolling spread" or "margin over copper") in copper foil: producers do not earn the copper price — they earn the per-kilogram fee added on top of LME copper, which is what they convert thin copper sheets into ultra-thin (4-6 μm) foil for. When EV demand soared in 2021-22, processing fees spiked; as Chinese capacity flooded the market in 2024-25, processing fees collapsed. The industry's profitability lives in this fee, not the copper price.

In semi test sockets, the unit of value is a per-socket ASP of roughly $69 to over $690 depending on application (HBM and large-area sockets command the premium). Sockets are designed and qualified to a specific chip; once qualified, they ship for the chip's commercial life — which gives the industry switching-cost economics that look more like specialty equipment than chemicals. ISC is the world's #1 socket producer per its 2023 acquisition disclosures, and SKC's recent commentary emphasizes shifting mix toward HBM and large-area sockets.

In commodity petrochemicals, margin = product spread minus feedstock, period. There is essentially no differentiation; PG and PO are global commodities priced off propylene. Lotte Chemical, BASF, LyondellBasell, Wanhua and a wave of Chinese capacity all sell substantially the same molecule. SKC's 2022→2024 PG-styrene-monomer revenue collapse from $1.35B to $0.81B is a textbook commodity-cycle event, not a company-execution failure.

Reading the chart. Indicative bands compiled from peer 2024 disclosures (Hansol Chemical 23% EBITDA margin, LEENO Industrial test sockets ~39× EV/EBITDA; Lotte Energy Materials negative EBITDA at trough). The pattern: the closer to the chip, the wider the spread. Test sockets have specialty-equipment economics; copper foil and PG/PO are commodity-like with margin compressed in downcycles. The same revenue won is not the same earnings won — and a mix shift toward semis is the central re-rating lever.

3. Demand, Supply, and the Cycle

The three industries have uncorrelated cycles, which is both an opportunity (diversification) and a curse (no single positive catalyst lifts the whole company).

The cycle pattern that matters. In copper foil, volume moves first, then utilization, then processing fee, then margin. The 2022-2024 episode is textbook: Chinese capacity ramped, EV demand growth slowed, plants ran below 70% utilization, processing fees fell from ~$8/kg to ~$4/kg, and margins collapsed. Recovery requires either supply discipline (slow) or step-change demand (ESS, 4680 cells, advanced batteries). SKC's 133% YoY North American ESS growth in 2025 is the first credible recovery signal, but it is from a low base.

In semi materials, the cycle hits differently. Sockets ride wafer-start volumes and qualification cadence: when a fab runs more wafers, more chips need testing, more sockets ship. AI/HBM has lifted test intensity per chip materially since 2024, which is why ISC printed the highest revenue in its history and why SKC guides >20% YoY growth in 2026.

In commodity petrochemicals, the cycle hits fastest and hardest because spreads can flip negative within a quarter. The $50M operating loss in chemicals in 2025 is consistent with the broader Northeast Asian PG/PO/SM downcycle driven by Chinese over-build. Recovery here typically requires plant closures elsewhere (regional rationalization), not just demand.

4. Competitive Structure

Each industry has a different concentration profile, and SKC's position varies by segment from "global niche leader" (test sockets via ISC) to "regional player" (copper foil) to "Korean pricing-taker" (PG/PO).

What the multiples reveal. LEENO trades at 22× EV/Revenue and 39× EV/EBITDA because the test-socket business has specialty-equipment economics — high margins, customer lock-in, AI tailwind. Hansol Chemical trades at 3.6× EV/Revenue as a focused semi precursor name. Copper foil players trade at 3-5× EV/Revenue with negative or compressed EBITDA — the market is paying for capacity, not earnings. Lotte Chemical trades at 0.6× EV/Revenue — pure commodity at the trough. The multiple spread tells the investor where the global market is paying for differentiation: the closer to the chip, the higher the multiple, by an order of magnitude.

The structural read. SKC sits in industries with opposite buyer-power profiles. In test sockets and glass substrates, the seller has design-in lock-in over a 1-3 year qualification cycle and earns specialty rents until the next chip generation. In copper foil and PG/PO, the buyer is fewer and more concentrated than the seller — three Korean cell-makers (Samsung SDI, LG Energy Solution, SK On) buy from at least five large foil suppliers, and BASF/Lotte/Wanhua compete on PG/PO into a fragmented industrial buyer base. Buyer concentration is the single best predictor of who keeps the margin in each industry.

5. Regulation, Technology, and Rules of the Game

These materials industries are increasingly shaped by trade and industrial policy, not just product chemistry. Two dominant rule-sets — US IRA/CHIPS and EU subsidy frameworks — are actively redirecting capacity to non-Chinese geographies, which is a tailwind for Korean producers like SKC if they have ex-China plants.

The pattern. Almost every active rule-change is a decoupling tailwind for Korean specialty material producers. The CHIPS Act funded the only commercial glass-substrate plant in the world at SKC's Absolics. The IRA's FEOC rules, by penalizing Chinese-content batteries in the US, have translated directly into surging copper-foil demand for SKC's Malaysia and (eventually) Poland plants. EU subsidy is offsetting plant capex. None of these tailwinds is yet reflected in current commodity pricing, but each shapes the cycle that follows the current trough. The technology shift to glass substrates is the lowest-probability, highest-payoff option in the portfolio: published claims point to >40% power efficiency improvement and >25% chip thickness reduction, and a first qualifier at NVIDIA/Google would capture multi-year design-in.

6. The Metrics Professionals Watch

Generic "operating margin" hides what matters in these industries. The metrics below are the few that actually explain whether the cycle is improving or deteriorating, and where to find each.

Why these eight, and not the standard ratios. Operating margin and ROIC are lagging indicators — they tell you what already happened. The metrics above tell you what is about to happen: processing fees and chemical spreads turn one to two quarters before margins. HBM-socket mix turns earlier than ISC's blended margin. Glass-substrate qualifications are binary events that re-rate the entire Absolics franchise overnight. Net debt / equity is the cycle-cushion KPI — and at FY2025 SKC's debt-to-assets is 70.0%, materially higher than the 63-65% range it ran in 2020-2023, which is why the ~$680M 2026 capital raise was necessary.

7. Where SKC Co., Ltd. Fits

SKC is best understood not as one industry participant but as a holding company whose subsidiaries each occupy a different industry position. The investor's frame should be sum-of-the-parts, not consolidated commodity-chemical comparable.

What this means for the rest of the report. Every section that follows should treat SKC as two valuable business (semi materials and glass substrate) plus two cyclical drags (copper foil and petrochem) plus one option (biodegradable plastics). The composite operating loss of $210M in 2025 does not describe one struggling business; it describes the algebraic sum of a $41.5M operating profit at semis, a $120.5M loss at copper foil, a $50M loss at chemicals, and $35M+ in pre-revenue costs at new business. Cycle recovery in any one of the loss-makers — without further deterioration in semis — would change the consolidated picture more than any management initiative could.

8. What to Watch First

The investor's industry watchlist is the short set of observable signals that would tell you whether the backdrop is improving or deteriorating, ranked by speed of read-through.

The single most important leading indicator is the copper-foil processing fee. It is the cleanest commodity-cycle signal in the entire portfolio, it leads margins by one to two quarters, and it is the only metric that can independently move SKC's largest loss-making segment back to break-even. Watch it before the headlines.

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

Know the Business

SKC is not a specialty chemicals company; it is a South Korean holding company that owns four unrelated material businesses plus a 45% stake in a separately-listed semiconductor test-socket maker. The consolidated 2025 operating loss of $210M obscures the only fact that matters for valuation: one of the four pieces (ISC, semi materials) is a high-margin AI-leveraged business worth more on its own than the rest of the group combined, and the market is partway to recognising that. Read SKC consolidated and you misvalue it; read it as a sum-of-the-parts and the investment question becomes specific and tractable.

1. How This Business Actually Works

SKC is four economic engines bolted together, run from a parent shell with debt. Three of them are wholly-owned operating subsidiaries; one (ISC) is a 45.03%-owned listed company that SKC consolidates because of board control. The four engines have nothing in common — different customers, different cycles, different unit economics, different competitors. The parent's job is allocating capital between them. Right now, that means funding losses in copper foil and chemicals while the AI test-socket business prints record results.

The economic point. A $152M-revenue test-socket business produced $41M of operating profit (27% margin) while a $753M chemical business lost $50M. That is not one company having a bad year; it is four different industries showing through the consolidated P&L. Margin doesn't compound across these engines — it averages, badly. The reinvestment runway also doesn't transfer: ISC cannot absorb the capital that copper foil needs, and copper foil cannot use ISC's AI-driven volume growth. The parent moves capital between segments, takes on debt to do it, and earns whatever spread remains after segment-level operating drag and corporate cost.

Read the contrast. The opportunity sits in valuing the parts separately rather than averaging them — the only path that lets the small profitable engine carry weight against the larger drags.

2. The Playing Field

There is no single peer for SKC because SKC sits in three industries. The only honest peer set is one that breaks the company into its parts and finds an economic substitute for each. The multiples below show why this matters: the spread between LEENO (test sockets) and Lotte Chemical (commodity petchem) is more than 30× on EV/EBITDA — the same $1M of revenue is worth a wildly different amount depending on which engine it came from.

Where SKC sits in the spread. SKC trades at 2.6× EV/Revenue — between Lotte Chemical (0.6×) and Hansol Chemical (3.6×) — which would be roughly fair if SKC were just chemicals. It is well below LEENO's 21.9× even though SKC owns 45% of ISC, the test-socket market leader. This gap is the entire SOTP argument: the market discounts the consolidated entity at near-petchem multiples even though the cleanest profit engine inside it deserves test-socket multiples.

The picture. Profitable specialty names (LEENO, Hansol Chemical) sit upper-right. Cyclicals at trough sit lower-left. SKC is anchored bottom-left — paying chemicals/foil multiples for a portfolio that contains one of the upper-right businesses through its ISC stake. The investment question is whether the rest of the portfolio is worth less than zero, or whether the market has correctly identified that the ISC stake is being diluted by the rest.

What "good" looks like in this peer set. Hansol Chemical is the cleanest comparable for what a specialty Korean chemicals business should earn at scale: 24% EBITDA margin, mid-teens ROE, profitable through every cycle since 2010. SKC ran a 19.6% operating margin in 2021, which proves the assets can earn — but it has not put two consecutive profitable years together since. The peer that flatters SKC is LEENO; the peer that judges SKC honestly is Hansol Chemical.

3. Is This Business Cyclical?

SKC is exposed to three uncorrelated cycles, which is both the curse and the option. The cycles do not net to "diversification" — they net to "no single positive catalyst rescues the consolidated number." Recovery in copper foil alone leaves the chemical drag; recovery in chemicals alone leaves the foil drag; semi materials alone are too small to absorb either. Two of three need to inflect together.

The 2021 peak vs 2025 trough. Peak operating income ($331M in 2021) coincided with high copper-foil processing fees, peak EV demand growth, and pre-Chinese-capacity-glut petrochem spreads. The trough since 2023 reflects: (1) 50%+ Chinese copper-foil capacity additions collapsing processing fees from roughly $8/kg to under $4/kg; (2) PG/PO/SM spreads near zero on Chinese cracker over-build; (3) front-loaded Absolics and SK leaveo investment with no offsetting revenue. None of these is a company-execution failure — they are textbook commodity cycles. The asymmetry is that two of the three are commodity cycles that revert; one (semi materials) is a structural growth business that has just begun.

The 1Q26 read-through. Three things happened simultaneously: the test-socket business posted another record (+236% YoY operating profit on AI demand), the chemical segment swung to a small profit on Middle East supply disruption widening PG/SM spreads, and copper foil narrowed losses on ESS volume (+390% YoY North America). For the first time since 2Q23, consolidated EBITDA went positive. It is not yet a cycle inflection; it is a single quarter where two of the three cycles moved together. That is the conditions test for the rest of the year. If chemical spreads hold and ISC keeps growing, the consolidated number can return to break-even on its own without a copper-foil recovery.

Where each cycle hits the P&L first. In copper foil, volume and utilization move first, then processing fee, then margin. In test sockets, the cycle starts at customer wafer-starts and HBM mix — leading SKC's reported revenue by a quarter. In chemicals, spreads can flip negative within a quarter and recovery requires regional plant closures (slow). The investor's job is to watch these leading indicators in exactly that order.

4. The Metrics That Actually Matter

The standard ratios — operating margin, ROE, asset turnover — describe the consolidated past. They do not describe what is about to happen, because they blend three industries together. Below are the few metrics that actually drive value creation and failure here.

Why these and not standard ratios. Operating margin tells you that 2025 was a loss year — it does not tell you which engine is recovering or by how much. The ISC HBM mix is the single best leading indicator of segment value because it directly maps to ASP and to the multiple LEENO trades at. The copper-foil processing fee is the only metric that moves the largest loss-making segment toward break-even — watch the fee, not the volume. The PG/SM spread is the chemical segment's entire P&L in one number. Net debt / equity is the cycle-cushion metric: at 70.0% debt-to-assets in FY25 (vs 63-65% in 2020-2023), SKC is approaching the point where the parent would need to fund growth from new equity — which is why a rights offering was announced for June 2026 and roughly $616M of asset rebalancing was disclosed in 4Q25.

Reading the balance-sheet pressure. Equity attributable to parent fell from $1,663M in 2020 to $574M in 2025 — book value collapsed by more than half during the trough. The rights offering scheduled for June 2026 is a direct response: the parent is rebuilding equity to keep capex flowing through copper-foil ramp and Absolics qualification without breaching covenants. The investor watching debt/equity has 1-2 quarters of warning before any further capital action; the investor watching consolidated operating income gets blindsided.

5. What Is This Business Worth?

SKC must be valued sum-of-the-parts. Consolidated multiples are misleading because the parts have different multiples by an order of magnitude, and one of them is separately listed. A reader who says "SKC is loss-making, therefore EV/Revenue at 2.6× is fair against chemicals peers" is missing the only point that matters: SKC owns 45.03% of a publicly-traded test-socket maker (ISC, KOSDAQ:095340) whose own market cap is $3,652M — meaning the ISC stake alone is worth roughly $1,644M against SKC's $4,117M total market cap.

The two valuation questions, restated.

First — is the ISC mark sustainable? ISC trades at 95× trailing P/E and roughly 22× the implied EV/Revenue of LEENO (its closest pure-play). That premium is paid for AI/HBM design-in lock and rapid revenue growth (semi materials operating profit grew 35% in FY25, with management guiding 20%+ in FY26). If the AI capex cycle holds, the ISC stake holds value. If AI capex disappoints — or if Samsung/SK hynix HBM growth slows materially — the ISC mark is the first thing to compress, and SKC compresses with it. The single biggest risk in this stock is not SK nexilis, it is ISC's own multiple.

Second — what is everything else worth? Stripping the ISC stake from SKC's market cap leaves about $2.5B of "implicit value" that the market is paying for SK nexilis + SK picglobal + Absolics + SK leaveo, less the share of consolidated net debt that sits outside ISC. SK nexilis at replacement cost or trough through-cycle is plausibly worth $400-700M. SK picglobal at trough peer multiples is worth $200-350M. Absolics is the option — anywhere from $0 (loses the qualification race to Samsung 2027) to $700M+ (named NVIDIA/Google customer). The implied number is consistent with copper foil getting credit for replacement value and Absolics being valued near zero — which is fair given that no commercial qualification has been announced.

What would support a premium. Two paths, in order: (1) a named hyperscaler qualification at Absolics that re-rates the glass-substrate option from "if" to "when"; (2) ~30% recovery in copper-foil processing fees that moves SK nexilis from a $120M annual operating loss toward break-even. What would justify a discount. ISC's multiple compressing on AI capex disappointment; the rights offering diluting more than expected; chemical spreads staying near zero; or a second capital action becoming necessary.

6. What I'd Tell a Young Analyst

Three things, in order.

One — value the parts before reading the consolidated number. Mark the ISC stake at the daily KOSDAQ price; everything else can wait. If you skip this step, you will misvalue SKC by half. The single most important number on the SKC tearsheet is not consolidated revenue or operating loss — it is ISC's market cap and SKC's stake percentage.

Two — the leading indicator hierarchy is fixed and short. ISC's quarterly HBM/large-area socket mix tells you about the test-socket franchise before the segment number prints. The copper-foil processing fee tells you about SK nexilis before the loss prints. The PG/SM spread tells you about chemicals before the spread compresses or recovers. Net debt/equity tells you about parent capacity before a capital raise. Watch these four; ignore consolidated EPS.

Three — the asymmetry is in the option, not the cycle. The cyclical recovery in copper foil and chemicals is path-dependent and slow; the AI/HBM growth at ISC is already happening; the glass-substrate optionality at Absolics is binary. The thesis that justifies owning SKC is some combination of "ISC keeps compounding" and "Absolics qualifies first." The thesis that justifies avoiding SKC is "ISC's multiple compresses while the rights offering dilutes." There is no middle case where consolidated metrics matter. Think in parts, not in totals — that is the only way this stock pays you.

Competition — Who Can Hurt SKC, and What Holds

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

SKC does not have one competitive position; it has three. Each operating engine fights a different war, against a different set of names, under a different rule book. The investor question is not "does SKC have a moat" — it is which of its four engines has one, how durable each is, and which competitor is most likely to compress the parts the bull case depends on.

Competitive Bottom Line

SKC's "moat" is two real moats stapled to two commodity-cycle losers. The two real moats — ISC's memory/HBM test-socket franchise (45.03%-owned, separately listed as KOSDAQ:095340) and Absolics' status as the only commercial-scale glass-substrate line in the world — are both narrow, customer-by-customer franchises with multi-year qualification cycles that look more like specialty equipment than chemicals. The two commodity losers — SK nexilis (battery copper foil) and SK picglobal (PG/PO/SM) — are losing money at the trough of a Chinese-capacity-driven cycle, and neither has a structural advantage that prevents the next cycle from looking the same.

The competitor that matters most is not a single name; it is a category — Chinese copper-foil producers (Wason, Nuode, CCP) — whose 2022-25 capacity additions have wiped roughly half the per-kg processing fee out of the entire foil industry. That dynamic, more than any Korean peer, is what keeps SK nexilis loss-making. Within the listed Korean peer set, Lotte Energy Materials is the head-to-head copper-foil rival, LEENO Industrial is the cleanest mirror for what test-socket economics should look like (and the multiple ISC trades at), and Hansol Chemical is the cleanest reproach to SKC's parent-level execution: same country, similar specialty-chemical raw materials, but profitable through every cycle for over a decade.

The Right Peer Set

There is no single "SKC peer" because SKC operates in four distinct industries. The honest peer set covers each major engine separately, with one petrochem benchmark for the chemicals segment.

Why these five. Each peer maps to one of SKC's economic engines. Hansol Chemical is the closest single-stock proxy for what a focused Korean specialty-chemicals platform earns — same country, same customer set (Samsung Electronics, SK hynix), but pure-play and profitable through every cycle since 2010. LEENO Industrial is the only listed pure-play test-socket name in Korea and the trading benchmark for ISC's multiple. Lotte Energy Materials is the direct copper-foil rival — same product (elecfoil), same Samsung SDI / LG ES / SK On customer base, similar Malaysia-and-Korea capacity footprint. Lotte Chemical is the regional cost-curve reference for PG/PO/SM. Solus Advanced Materials is the EU-focused copper-foil rival (Hungary plant) plus OLED materials — important because Solus's struggles in 1Q25 (consolidated EBITDA margin -2.1%, copper foil deeply unprofitable) confirm that SK nexilis's losses are an industry-wide condition, not idiosyncratic SKC execution.

Reading the chart. The market is paying for differentiation, not scale. LEENO at 21.9× sales sits alone upper-right because test-socket economics are specialty-equipment; Hansol Chemical sits in the comfortable middle as a profitable specialty-chemicals platform; SKC, Lotte Energy Materials, Solus and Lotte Chemical bunch in the lower-left because their consolidated economics are commodity-cyclical at the trough. SKC's market cap is bigger than every peer except LEENO — but its EBITDA margin is the worst of the group. That gap is the entire valuation argument: the market is paying SKC for option value (ISC stake, Absolics, eventual cycle recovery), not for current cash earning power.

The financial honesty test. Two of the five peers (Hansol, LEENO) are profitable; three are not. SKC sits firmly in the second group, and its operating loss as a percentage of revenue (-14.0%) was worse than every peer except Solus. Its debt load ($2,813M, more than 4× equity) is the most stretched in the set. The peer that beat SKC at SKC's own game is Hansol Chemical — same country, similar customer set, much smaller, far more profitable, with a balance sheet that doesn't need a rights offering.

Where The Company Wins

Four real edges. Each is narrower than SKC's official messaging implies, but each is supported by primary evidence.

On ISC, be precise. ISC is not the global #1 in test sockets — Cohu (US) leads the broader category, especially in high-end non-memory; Yamaichi and Yokowo are entrenched in Japan; LEENO and ISC dominate the Korean memory and HBM-adjacent sub-segment. Counterpoint Research data (2Q25) puts SK hynix (62%) and Samsung (17%) at 79% combined HBM share — and Korean memory makers prefer Korean socket suppliers on co-location, qualification speed, and IP control. That is the segment ISC is winning, and it is what carries SKC's profit engine today. The win is real but narrow — if AI capex slows or HBM share rotates away from Korea, the ISC mix-shift stalls.

On Absolics, be even more precise. First-mover in glass substrate is genuinely valuable because qualification cycles at NVIDIA / Google / Broadcom are 18-24 months; if Absolics is qualified before Samsung's 2027 commercial ramp, it captures a sole-source position for the qualifying chip generation. But "first to operate" is not the same as "first to be qualified", and as of FY25 there is no named hyperscaler customer disclosed. The win is conditional on something that has not yet happened.

The test-socket map. Cohu is bigger; LEENO is the cleanest pure-play; ISC's edge sits in the intersection of memory + HBM + Korean customer relationships. That intersection is the most attractive pocket of the test-socket market today, but it is not the whole market. Investors who treat ISC as "the global test-socket leader" overpay; investors who treat it as "the Korean memory test-socket leader during an AI capex super-cycle" pay for what is actually there.

Where Competitors Are Better

Four specific places where named peers do something SKC does not. None of these are generic — each maps to one engine.

Hansol is the painful comparison. Both companies sell into Samsung Electronics / SK hynix / Korean industrial buyers. Both are exposed to the AI / semi capex cycle. Hansol is one-tenth the consolidated size but earns more operating profit — and it has done so for 10+ consecutive years. The difference is portfolio choice: Hansol stayed focused on H2O2, peroxide, semi precursors and latex; SKC bought into copper foil at the top of the cycle (KCFT, ~$1B from KKR in 2019) and is now wearing the trough. Same country, same customer set, very different consolidated outcome.

The Lotte Energy Materials (formerly Iljin) reference is the head-to-head test in copper foil. Both companies cut Korean utilization to ~60% in 2H23, both expanded Malaysia, both forecast oversupply through 2025 (per KED Global trade press). The difference is contract visibility: Lotte Energy disclosed the ~$5.8B Samsung SDI contract through 2030 in 2022, before the trough; SK nexilis's equivalent contract architecture is less explicit. In a downcycle, contract visibility is the moat — and Lotte Energy's is more visible.

Read the utilization gap. A 27-30 point drop in plant utilization in 12 months is what the entire Korean copper-foil industry experienced in 2023. That is the cycle, not the company. The recovery condition is Chinese capacity discipline (closures, delays, slowdowns) — not anything Korean producers can do unilaterally. Whoever sustains the lowest cost-per-kg through the trough wins the recovery; that puts a premium on Malaysia ramps for both SK nexilis and Lotte Energy Materials, and a discount on Korea-only producers.

Threat Map

The threats below are ranked by what they would do to SKC's market cap, not by their probability. The two High-severity items are the ones that determine whether this thesis works at all.

Moat Watchpoints

Five measurable signals that an investor should watch quarter-by-quarter to know whether SKC's competitive position is strengthening or weakening. Each is independently observable from public disclosure.

Current Setup & Catalysts

Figures converted from Korean Won at historical FX rates — see data/company.json.fx_rates. Ratios, margins, multiples, and percentages are unitless and unchanged.

1. Current Setup in One Page

The stock is in the middle of a regime-change tape: SKC has rallied roughly +75% in six weeks into a ~$680M rights-offering close on 8 June 2026, while consensus is still printing UNDERPERFORM at $72. The market is watching three things at once — (i) does the 1Q26 EBITDA inflection hold in 2Q?, (ii) does the rights offering price as a clearing event or as a fresh dilution shock?, and (iii) does Absolics actually convert glass-substrate sample work into a named hyperscaler qualification by year-end? Three years of guidance misses, a CEO change six weeks ago, and a 30-day realised vol of 117% mean every print over the next 90 days will be marked harder than usual. The next 6 months are unusually event-rich for a Korean specialty-materials mid-cap; the calendar is not thin, but it is binary.

Recent Setup Rating: Mixed

---

2. What Changed in the Last 3-6 Months

The narrative arc. Three months ago the question was whether SKC could survive the cycle without further dilution and whether legacy losses would compound — both ostensibly answered by the 26 February rights announcement and the 5 February FY25 reset. Today the question is the opposite: whether the recent ~$34 rally ($72 → $109) has run ahead of the deliverables. Unresolved variables sit on the operating side: chemicals at risk of reverting if Mid-East PG tightness fades, copper-foil processing fees not yet recovering, Absolics pre-revenue with no named hyperscaler. The $410M FY25 below-the-line loss block — ~3× the operating loss — has not been disaggregated in English filings, leaving the consolidated burn mis-measured by anyone outside DART Korea.

---

3. What the Market Is Watching Now

The live debate is unusual: the consensus is bearish (UNDERPERFORM), the tape is screaming bullish (+75% in six weeks), and the company is days away from issuing 22% new shares. All three positions cannot be right. The next 30–90 days resolve which one was.

---

4. Ranked Catalyst Timeline

Reading the timeline. Five of the top six catalysts land in the next 6 months — three of them inside 90 days. This is not a thin calendar. The unusual feature is that the three calendar-confirmed events (rights subscription, listing, Q2 earnings) sit before the soft window for Absolics qualification, so the underwriting question gets answered in chronological order: first whether the dilution is absorbed, then whether the operations sustain, and only then whether the optionality pays.

---

5. Impact Matrix

The matrix concentrates on resolution power, not information value. The rights close and the 2Q print collectively decide whether the bull rally extends or unwinds; the Absolics qualification window decides whether the dilution paid; the ISC multiple decides whether the SOTP stays intact through any of the above. Items further down add flavour but do not, on their own, force the debate to update.

---

6. Next 90 Days

---

7. What Would Change the View

The two or three observable signals that would most change the investment debate over the next six months are: (1) the 8 June listing-day tape, because a clean clearing turns the dilution from an overhang into a recap and removes the single most-cited reason consensus targets sit at $72; (2) the 2Q 2026 EBITDA print on or around 5 August, because a second consecutive positive print converts 1Q26 from "flattering 4Q big-bath comp" into "structural inflection," the precise question the bear case rests on (forensics-claude.md scorecard B7); and (3) any named hyperscaler qualification at Absolics in 2H26, because that is the only catalyst that can re-rate the $401M of dilution proceeds from sunk cost to optioned upside — and is also the binary cover signal the bear case names explicitly. Secondary signals worth tracking are an ISC standalone compression of 20%+ on AI capex doubt (which would test the SOTP simultaneously with operations), an adverse copper-foil patent ruling (which would compound SK nexilis loss exposure not currently in sell-side models), and a sell-side revision wave that pulls Nomura's $61 or JPMorgan's $49 targets toward spot (which would mean the institutional underwriting that has been absent finally arrives). What would not change the view: another disposal, another SK-affiliate-led capital injection, or an investor-day deck — those are continuations of the 2025 pattern, not new information.

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — the SOTP works on paper, but the two load-bearing claims (1Q26 was a structural inflection, and ISC's 95× P/E holds) both resolve inside one earnings cycle, and the price has already run +75% in six weeks at 10-year-extreme volatility. Bull and Bear agree on the same balance sheet, the same ISC mark, and the same 1Q26 P&L; they disagree on whether the inflection is real and whether ISC's multiple is durable. The decisive tension is whether 2Q26 EBITDA stays positive without the Mid-East PG-spread tailwind — that single print resolves more of the debate than any other variable. Owning the stock today is paying for confirmation that has not yet been delivered into a tape that has already priced most of it. Wait for the 2Q26 print (mid-August 2026) and the post-rights cap structure to clear, then re-underwrite.

Bull Case

Bull's price target: $150 over 12–15 months (through Q2 2027 earnings). Method is sum-of-parts: ISC parent share at LEENO premium for sustained AI demand (~$2.04B), SK nexilis at through-cycle replacement value with FEOC-driven NA volume (~$612M), SK picglobal at trough peer multiple post-1Q26 (~$340M), Absolics option re-rated to ~$408M on visible 1H27 hyperscaler qualification, plus $680M rights cash, less ~$1.36B allocated parent net debt ≈ ~$2.72B equity across ~46M post-rights shares ≈ $59 floor; bull-case re-rating drives the $136–163 upper-bound zone (also the prior 2021 ATH range). Primary catalyst is the 2Q26 print in mid-August 2026 — a second consecutive positive consolidated EBITDA quarter that confirms 1Q26 was structural. Disconfirming signal: 2Q26 EBITDA reverts negative AND ISC standalone compresses ≥20% from $3.65B — the conjunction breaks the SOTP and the cycle leg simultaneously.

Bear Case

Bear's downside target: $65 (−41% from $109) over 12–15 months. Method stacks three compressions: (a) mechanical ~22% dilution from June rights takes $109 to ~$85 holding EV constant, (b) ISC multiple compression from 95× P/E toward LEENO's 39× EV/EBITDA cuts SKC's ISC stake from ~$1.64B toward ~$884M (~$17/share), (c) chemical PG tailwind reverts and Malaysia copper-foil EBITDA-positive proves a one-quarter event. Lands $61–68, between Nomura's $61 and consensus $72; anchor at $65. Primary trigger is the June 8 rights listing crystallizing dilution arithmetic, followed by 2Q26 if chemical OP reverts and EBITDA prints negative again. Cover signal: a named hyperscaler qualification at Absolics (NVIDIA / Google / Broadcom / Samsung) that re-rates the glass-substrate option from $0–136M to $680M+; or two consecutive quarters of consolidated EBITDA > +$20M with ISC HBM mix still rising (softer secondary).

The Real Debate

Verdict

Watchlist. Bear carries marginally more weight today because two of the three bear points (the $405M unexplained below-the-line wedge widening every year, and the 117% realized-vol blow-off into uniformly negative sell-side coverage) are observed facts that do not depend on a future event, while the strongest bull points (1Q26 inflection, capital reset clearing) require the 2Q26 print to confirm. The single most decisive tension is whether 1Q26 was a structural three-engine inflection or a Q4-big-bath / Mid-East-PG artifact — and that resolves on one earnings date in mid-August 2026, six weeks after the rights listing has cleared the dilution arithmetic. The bull case could still hold: the ISC mark is real, listed, and AI-leveraged, and a positive 2Q26 paired with an Absolics named-hyperscaler announcement could re-rate the SOTP fast enough that early entry would pay. The condition that would shift this to Lean Long is a 2Q26 consolidated EBITDA print > +$14M with chemical OP still positive, accompanied by post-listing tape absorption that does not give back the rights-offering discount within four weeks. The condition that would shift it to Avoid is a 2Q26 EBITDA reversion to negative paired with any ISC standalone compression ≥15% — which would break both the cycle and the SOTP legs at once.

Moat — What Protects This Business, If Anything

Figures converted from Korean won at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

A moat is a durable economic advantage that lets a company protect returns, margins, share, or customer relationships better than its competitors over a full cycle. The test is not whether the company is currently winning — it is whether the mechanism that lets it win can survive a price war, a downcycle, a technology shift, or a determined entrant.

For SKC, the answer is unusual: the company does not have a moat at the consolidated level — it has one real moat, one option-on-a-moat, and two cyclical commodity businesses that have no moat at all. Read consolidated, you will conclude SKC is a poorly-defended cyclical that destroys capital. Read at the part level, you find a high-quality test-socket franchise inside a broader holding company that is structurally subscale.

1. Moat in One Page

Conclusion: Narrow moat — and only at one of four operating engines. The one defensible advantage is ISC's switching-cost moat in Korean memory and HBM test sockets (45.03% owned, separately listed as KOSDAQ:095340), where multi-year customer qualification cycles, co-location with SK hynix and Samsung, and per-socket ASPs of $70–690 produce 27%+ operating margins through the cycle. Everything else is weaker: Absolics is a first-mover option that has not yet been awarded a named hyperscaler customer; SK nexilis copper foil competes in a Chinese-capacity-flooded commodity where five Korean producers are loss-making at the trough; SK picglobal chemicals is a sub-scale petrochem participant with no cost-curve advantage. The consolidated entity blends these together at the worst possible ratio: 12% of FY2025 revenue from the moated segment, 88% from non-moated or commodity businesses.

Moat Rating: Narrow  ·  Weakest Link: ISC concentration risk

The two strongest pieces of evidence. First, ISC delivered $41M of operating profit on $152M of revenue (27% margin) in FY2025 while the rest of the consolidated entity lost roughly $252M — a margin gap of more than 40 percentage points between the moated segment and the non-moated portfolio. Second, ISC's 1Q26 operating profit grew +236% YoY on AI/HBM design-in wins, against an industry where Cohu (the global #1 in non-memory test) and Yamaichi (Japan) are larger and have not been able to replicate ISC's position with Korean memory makers. That mix-shift has held through a full year of consolidated losses elsewhere — the moat has paid through stress.

The two biggest weaknesses. First, the consolidated entity has been free-cash-flow-negative for three years, parent equity has fallen 54% since FY2021, and the rights offering scheduled for June 2026 dilutes minorities specifically because the un-moated segments cannot fund their own capex. Second, ISC's customer base is concentrated in two names (Samsung, SK hynix) that together control 79% of HBM share — if AI capex disappoints or HBM share rotates to Micron, the test-socket franchise compresses faster than any other segment.

2. Sources of Advantage

The five moat archetypes mapped against SKC's actual evidence base. Three categories show real, narrow advantages; four categories show no evidence at all.

The shape of the table matters as much as the contents. Of the eight archetypes, only one (ISC switching costs) has high-quality proof; one (Absolics first-mover) has plausible mechanism but no commercial proof; two (regulatory and SK Group affiliate access) are real but narrow and shared with competitors; four show no evidence at all. A moat at one segment that contributes 12% of revenue is not a moat at the company level — it is a moat at one subsidiary. That is the central distinction this tab is built to make.

3. Evidence the Moat Works

Six items of evidence — six different lenses — that test whether the alleged switching-cost moat at ISC is real, and whether the broader portfolio shows any sign of pricing power, retention, or share gain.

Read the ledger. Items 1–3 (ISC margin, growth, market-confirmed multiples) build a coherent case for a real but narrow moat at one segment. Items 4–5 (consolidated returns, Hansol comparison) refute a company-level moat. Items 6–7 mix support and refute — regulatory tailwinds are real but shared, and Absolics is unconfirmed. Item 8 confirms the cyclical character of the rest. The honest reading is: the test-socket switching-cost moat is real; the rest of SKC operates in markets without protectable economics.

The chart shows the moat at one segment, the lack of moat at three. Even ISC's 27% margin sits below LEENO's 39% EBITDA margin — meaning ISC is not the test-socket leader, just a Korean memory specialist. The other three engines earn nothing remotely resembling a moat-grade margin.

4. Where the Moat Is Weak or Unproven

Six places where SKC's claimed advantages are weaker than the company's messaging implies.

5. Moat vs Competitors

Each peer has one specific moat (or lack thereof) that puts SKC in context. The picture: SKC is the most diversified, but diversification across commodities does not create a moat; concentration into a defensible niche does.

The three peers most relevant to the SKC moat case. First, LEENO is what ISC could be if you owned it pure — wider moat, 39% EBITDA margin, no copper-foil drag. Investors who want test-socket exposure can buy LEENO directly, which is why ISC trades at a discount when held inside SKC. Second, Hansol Chemical is the painful comparison: same country, same customers, profitable through every cycle, no rights offering — proving that a focused Korean specialty-materials portfolio can compound through downturns if construction is disciplined. Third, Lotte Energy Materials has explicit ~$6.7B contract visibility through 2030 — in a downcycle, contract visibility is the moat, and SK nexilis's equivalent is less explicit. The peer set as a whole shows that focused, single-segment players have wider moats than SKC's diversified portfolio.

6. Durability Under Stress

A moat only matters if it survives stress. Below: six stress scenarios that test where SKC's narrow moat would break, hold, or strengthen.

The pattern. The narrow moat at ISC has already been stress-tested through 2023–25 and has held — that is the strongest single piece of evidence the moat is real. The non-moated segments have failed every test that matters: foil, chemicals, and the parent balance sheet are all worse than they were three years ago. The investment question reduces to whether ISC's moat will survive the next stress (Cohu/Yamaichi entry, AI capex slowing) at the same time that the non-moated segments remain a drag.

7. Where SKC Co., Ltd. Fits

The moat lives at one place inside this company: the 45.03% stake in ISC. Everything else is either an option, a cyclical bet, or a commodity drag.

The single critical fact. SKC's market cap of $4.18B contains roughly $1.64B of mark-to-market ISC stake — meaning the implied value of everything-other-than-ISC is roughly $2.47B. That residual is paying for SK nexilis (no moat), SK picglobal (no moat), Absolics (option), SK leaveo (option), less the parent's net debt. The moat is concentrated in a single subsidiary, separately listed, and partially diluted by the rest of the portfolio.

Reading the picture. Roughly $1.64B of moated value (ISC) sits inside $4.18B of market cap. The rest is option value (Absolics, SK leaveo) and cyclical replacement-cost value (SK nexilis, SK picglobal) less consolidated net debt. A wide-moat investor underwriting SKC pays full multiples for one quarter of the company. That is the exact reason valuation requires SOTP, not consolidated multiples — and the exact reason this is not a "wide moat" company in the Morningstar sense.

8. What to Watch

Six measurable signals. The first one is the moat itself; the next three test whether competitors are closing in; the last two test whether the parent can keep funding the moat without diluting it away.

The first moat signal to watch is ISC's quarterly HBM / large-area socket revenue mix — it is the only direct, observable proxy for whether the company-level switching-cost moat is widening or narrowing, and it leads ISC's own segment margin by one quarter. If the mix flattens before the trough signals turn, the SKC moat case is materially weaker than the consolidated market cap implies.

Figures converted from KRW at historical period-end FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

The Forensic Verdict

SKC's accounting is not the source of the problem — the business is. But the way the numbers are presented makes the underlying damage harder to underwrite than it should be. The continuing-operations P&L has been sub-zero for three straight years, yet pretax losses have run roughly 2.4x to 3.0x larger than reported operating losses (FY25 OP of -$211M versus pretax of -$620M), with the missing -$410M buried in below-the-line items the English filings never break out. The full audited cash-flow statement is filed only on DART in Korean, so investors outside the home market cannot directly verify CFO. Repeated divestitures — PET film (2022), CMP Pad/FCCL/Blank Mask/CMP Slurry (2024-25), Fine Ceramics (2024) — re-baseline "continuing operations" each year, and Q4 2025 layered visible big-bath signals in EV battery materials and Chemical (write-down of "manufacturing-equipment optimization") just as a rights offering was being announced. We grade the file Elevated, not High — there is no restatement, auditor change, or material-weakness disclosure, the audit committee is fully independent and active, and balance-sheet hygiene metrics like DSO are clean. The single data point that would change the grade is a clean, English-language consolidated cash-flow statement showing that 2025's $443M cash build came from genuine working-capital release plus the disclosed $616M asset-rebalancing program — not from receivable factoring or supplier-finance lifelines. Until that arrives, treat headline cash and headline operating loss as informationally incomplete.

Grade: Elevated. The accounting risk here is opacity-driven, not manipulation-driven. The English-language filings do not lie; they under-disclose. A reader cannot, from public English data alone, confirm where -$410M of FY25 below-the-line losses came from, why non-controlling interests gained $10M in a year the parent lost $507M, or how $443M of cash was actually built. None of these is a fraud signal in isolation. Together, they require an underwriting discount.

Shenanigans scorecard

Breeding Ground

The breeding-ground signal is concentrated ownership inside a chaebol ecosystem, balanced by a board that looks well-functioning on paper. The amplifier and the dampener largely cancel.

The board structure does what governance is supposed to do — independent majority, fully-independent audit and internal-transactions committees, no opposed votes but two modified votes recorded in 2022, ISO 37301 compliance certification newly obtained. The KCGS named SKC an "Excellent Company" in governance in 2024. Against that, the parent SK Inc. holds roughly 40% of shares, the major operating subsidiaries are co-owned with related parties (Hahn & Co. at SK nexilis, Apollo at Absolics), and detailed director compensation is disclosed only on DART in Korean. None of this is unusual for a Korean chaebol affiliate; it does mean an English-only investor is reading through a smaller window than a domestic counterpart.

The single breeding-ground signal that did not fire — the streak of beating expectations — fails to fire because there is nothing to beat: SKC has reported losses for three straight years. That cuts both ways. The earnings-management incentive to flatter results is muted; the survival incentive to time write-downs and divestitures around capital raises is not.

Earnings Quality

Earnings quality has three tiers: the operating line, the below-the-line gap, and the discontinued-operations cushion. Only the first looks like it reflects underlying economics. The other two require structural skepticism.

The pretax-to-operating gap

The widening wedge between the blue and red bars is the most material forensic signal in the file. From a clean $4M gap in FY22, non-operating items deteriorated to -$142M in FY23, -$262M in FY24, and -$410M in FY25. The English deck does not disaggregate this line. Plausible drivers — equity-method losses on Absolics (US glass-substrate JV, pre-revenue), impairment of investments in associates, finance costs on a leveraged balance sheet, FX losses, and likely write-downs of intangible assets — are individually visible elsewhere in the file (intangibles fell from $1,287M to $915M over FY23-25), but the income-statement attribution is missing.

This pattern is exactly what the playbook calls "hiding losses below the line": OP is the metric management leads with; the much larger pretax loss arrives later and is rarely re-quoted.

The discontinued-operations cushion

In four of the last six years, discontinued operations were materially larger than continuing operations — sometimes a tailwind (FY20, FY21, FY24) and sometimes a drag (FY22, FY23). FY24 is the most consequential: a +$84M discontinued-ops gain softened the headline net loss from -$393M (continuing) to -$309M (reported). In FY25 the company appears to have closed the divestiture cycle, so the cushion disappeared and the full continuing-operations loss flowed through. The optical improvement that any FY26 print could deliver should be measured against continuing-ops earnings only, not against the cushioned net-income line.

A related governance note: the number of consolidated entities collapsed from 42 in FY23 to 22 in FY24. That 20-entity reduction reshapes the comparable group and complicates any like-for-like FY24 vs FY23 read.

Margin and reserve hygiene

Operating margin has stabilized around -16% for two years, but net margin keeps deteriorating (-21.9% → -26.4% → -39.1%). The widening of the net-vs-OP wedge — from 7.5pp in FY23 to 22.5pp in FY25 — is the same below-the-line story restated as ratios.

Cash Flow Quality

This section is partially blocked by disclosure: SKC's full audited cash-flow statement is published only in Korean on DART. The English Sustainability Report and 4Q earnings release deliberately omit it. We can reconstruct directional cash flow from balance-sheet changes and from disclosed corporate actions, but we cannot run the standard CFO/NI test or accruals test cleanly.

The FY25 cash spike — from $274M to $721M, a +$447M build in a year of -$496M net loss — is the question. Management's own 2025-review slide answers most of it: $616M of asset rebalancing (CMP Pad $231M + FCCL $66M + Blank Mask $47M + CMP Slurry $8M = $351M of disposals, plus $266M of exchangeable-bond issuance). Reconciling roughly: -$496M loss + non-cash D&A ~$130M + disposal proceeds $351M + EB $266M + working-capital and FX = ~$275-450M cash build, in the right ballpark for the observed +$447M.

Inventory rebuilt from $160M to $235M in FY25 — that consumes cash, which is a clean signal: cash strength was not built by under-purchasing inventory. Trade receivables for FY25 are not separately disclosed in the 4Q earnings release (the deck shows only aggregate current assets), which is itself a yellow disclosure gap.

The forensic conclusion is: FY25 cash flow looks reasonable but is fundamentally non-recurring. Two large divestitures and an exchangeable bond covered three quarters of the build. Management explicitly described 2026 priorities as "cash flow-centric management" with "CAPEX discipline" and "non-core asset rebalancing option" — language that telegraphs continued reliance on disposal-driven cash and capital-markets access. A rights offering was announced in 1Q26 and is scheduled to list June 8, 2026.

Metric Hygiene

The metrics SKC leads with — segment revenue, segment OP, EBITDA, and the YoY/QoQ deltas in the 4Q deck — are consistent with the underlying statements but are framed to make the quarter look better than the cumulative print does.

The most underweighted metric in the file is the divergence between parent equity and non-controlling interests. Parent equity collapsed from $1,681M in FY21 to $574M in FY25 (a -66% draw in USD terms, -58% in home currency); NCI rose from $236M to $824M over the same window. That means co-investors at the subsidiary level — Hahn & Co at SK nexilis, Apollo and SK Inc. at Absolics — funded growth capex while the listed parent absorbed an outsized share of the operating losses. In FY25, parent net loss was -$507M against group net loss of -$496M, implying NCI booked a +$10M gain in a year the parent burned through $507M. That asymmetry is allowed under K-IFRS when losses occur in entities where the parent funded most of the equity, but it is not reader-friendly: the ratio that matters for SKC's listed-share holders is parent-attributable, which is meaningfully worse than the group line.

Tangible assets ramped $1,563M → $2,248M over FY22-24 (+44% in USD; +67% in home-currency terms) — the copper-foil capacity build in Malaysia and Poland plus Absolics in Georgia. Soft assets (intangibles + goodwill) drifted down $1,287M → $915M (-29% in USD) over FY23-25, suggesting some impairment did flow through, though the magnitude is not separately tabulated in the English filings. The capex/D&A ratio in FY24 was approximately 4.2× depreciation — deep growth-mode spending into a market that is now penalizing copper-foil supply with chronic operating losses. The forensic question for FY26 is whether further intangible/PP&E impairment will be required if Malaysia and Absolics ramps fall behind plan.

What to Underwrite Next

The forensic risk here does not change the direction of the investment thesis — it shapes the position size and the margin of safety required against the operational thesis. Five specific items belong in the next-quarter and next-AR diligence list:

1. The full audited cash-flow statement (DART, in Korean) for FY24 and FY25. The single missing piece. It would let an analyst test CFO/NI, accruals ratio, and working-capital contribution directly. Without it, one is reasoning from balance-sheet deltas. What changes the grade: a clean CFO ≥ -$140M excluding asset disposals, with working-capital contribution under $70M, would downgrade the file to "Watch."

2. Disaggregation of the $410M FY25 below-the-line losses. Specifically: equity-method losses on Absolics, finance costs, FX, impairment of investments in associates, and any goodwill/intangible impairment. Each is recoverable from the K-IFRS notes; they are simply not in the English deck. What changes the grade: if the bulk is finance cost + Absolics equity-method losses (recurring but predictable) rather than impairments (concentrated and lumpy), it is less concerning.

3. The post-rights-offering pro-forma balance sheet. The June 8, 2026 listing materializes the dilution. Watch parent equity, current ratio, retained earnings (currently negative at -$35M), and net debt for the recovery profile. What changes the grade: parent equity restored above $830M and current ratio above 1.0 in 2Q26 print would downgrade the file to "Watch."

4. Quantification of the Q4 2025 "one-time expenses." The 4Q deck describes "Recognition of one-time expenses" in EV battery materials and a "write-down of manufacturing equipment optimization" in Chemical without giving USD magnitudes. The 1Q26 deck already uses the phrase "narrowed operating loss given one-time costs recognition in 4Q25" — i.e. management is preparing the comparison. Watch FY26 OP for "ex-one-time" framing that would not have surfaced in a normal quarter.

5. Related-party transaction volume with SK Group affiliates. SK Inc. is the ~40% controlling shareholder. The Internal Transactions Committee meets 8-12× per year. Aggregate annual transaction volumes with SK affiliates (SK Inc., SK Discovery, SK Chemical, SK enpulse remnants) are filed in Korean only. What changes the grade: a sudden expansion of intra-group transaction volume during the rights-offering window would raise the file toward "High."

The file is Elevated, not High. Move it down to "Watch" when the consolidated cash-flow statement and the FY25 below-the-line breakdown become available in English. Move it up to "High" only if a new auditor finding, a fair-value adjustment dispute on Absolics, or an undisclosed related-party transaction appears.

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The People

Governance grade: C+. SKC checks every formal box that Korean and global ESG raters reward — majority-independent board, female chair, AA from MSCI — but the structural reality is an SK Group–controlled subsidiary that just installed a brand-new CEO, asked minorities to fund a $680M rights issue alongside two consecutive years of nine-figure losses, and discloses zero per-officer compensation in English. Trust the institutions; verify the alignment.

1. The People Running This Company

The CEO chair turned over six weeks ago. On 26 March 2026 the 53rd AGM appointed Kim Jong-woo as President & CEO of SKC, replacing Park Won-cheol who had run the company since 2022. Kim was named concurrent CEO of SK Nexilis (the copper-foil subsidiary) at the same restructuring. CFO Park Dong-ju was hired from SK Inc. in late 2025 and was elevated to inside director at the same AGM. The independent chair is Chae Eun-mi, ex-CEO of FedEx Korea, reappointed in March 2026 — the first woman to lead the SKC board.

The bench is credible on paper — McKinsey, Affinity Equity, Kim & Chang, Intel, SK Hynix, Lam Research — but it is overwhelmingly an SK Group bench. Kim Jong-woo, Park Dong-ju, Yoo Ji-han, and Kim Kee-dong are all SK Group lifers. The non-SK voices on the board are the four independents, and they were brought in to validate, not to challenge. The single most consequential outside hire is Kang Ji-ho at Absolics: $401M of the rights-issue proceeds are being routed to his unit, so his execution dictates whether the dilution pays.

2. What They Get Paid

SKC discloses board structure, but per-officer compensation tables sit in the Korean DART business report — not in the English Sustainability Report. What is visible is the machinery: a 75%-independent HR Evaluation & Remuneration Committee that met 10 times in 2024 (up from 5 in 2023) and a short-term incentive scheme tied to financial KPIs that MSCI specifically credited when upgrading SKC to AA.

MSCI ESG Rating: AA

In short: the system (committee independence, frequency, KPI linkage) reads well. The receipts are not in English.

3. Are They Aligned?

This is the section that decides the case. SKC has one parent (SK Inc., 40.64%) underwriting one rights issue ($680M) to fund one bet (Absolics) while two years of losses have already required $616M of asset disposals. Skin-in-the-game lives at the parent level, not the management level.

Ownership and control

The rights issue dominates the alignment story

The rights-issue mechanics are alignment-positive in two specific ways: SK Inc. is paying for ~120% of its pro-rata, which is more than passive support. And the ESOP was 132% oversubscribed — employees voting with their own won. They are also alignment-negative because the equity raise is happening after two years of losses, because the company can no longer borrow more (interest coverage is −4.6×), and minorities who don't subscribe will dilute substantially.

Capital allocation — the dilution & disposal pattern

The shareholder-friendly read: management is actively monetizing non-core assets to fund the strategic pivot, rather than letting cash burn through the income statement. The shareholder-unfriendly read: every cash-raising mechanism in the past 18 months has been dilutive or one-time. There is no buyback. The dividend was zero in FY24/FY25 (capital surplus + retained earnings collapsed from $776M to $−35M).

Insider activity & related parties

Detailed insider trading (Korean Form 4–equivalent) is filed only on DART in Korean. The English-language record is silent on individual director/officer transactions. What is visible:

• The Internal Trade Committee is 100% independent, met 12 times in 2024, attendance 97.3%, with 17 reported and 0 resolved-with-objection items. SKC sits inside the SK Group ecosystem (SK Inc. parent, SK Hynix sister, SK Materials cousins) — related-party flow is structural and constant, not occasional.
• The 2019 acquisition of KCFT (now SK nexilis) from KKR for ~$1 billion was the defining capital-allocation decision of the past decade. It was an arm's-length deal at its time, but SK nexilis is the largest source of impairment exposure in 2024–25.
• Park Won-cheol simultaneously served as SKC parent CEO and CEO of Absolics during 2022–March 2026 — material related-party self-dealing risk inside one person, now resolved by the CEO change.

Skin-in-the-game scorecard

Score: 6/10. SK Inc. is putting real money behind its conviction and so are rank-and-file employees through the ESOP. But there is no English-language evidence that SKC's named executive officers personally own a meaningful slug of the float, and the parent's interests dominate every alignment vector — including how the rights-issue economics get split. A clean 6 — not the 4 a less-engaged controlling shareholder would warrant, not the 8 a founder-CEO with personal ownership would.

4. Board Quality

The SKC board is what the SK Group calls a "model" inside its portfolio. It is genuinely better-than-average for Korea: 57% independence, two female directors (29%), the first female chair in the company's 53-year history, four monthly committees that pre-deliberate everything, and 80% compliance against the Korean Corporate Governance Code (industry average 63.5%). The audit committee is 100% independent, meets 13 times a year, and posts 100% attendance.

The expertise gap that matters: nobody on the board has direct lithium-ion battery materials or semiconductor advanced-packaging operating background. The technical knowledge to challenge management on Absolics or Malaysia copper-foil ramp lives outside this room. Park Si-won (ex-McKinsey/Affinity) and Jung Hyun-wook (CPA, ex-Seoul Semiconductor CFO) are the strongest commercial pushers; the rest are governance/legal/global generalists.

5. The Verdict

Governance Grade: C+ — Good Korean SK-affiliate governance, weak on alignment + pay transparency.

Strongest positives:

• 57% board independence, 100%-independent Audit and Internal Trade Committees, first-female chair, KCGS Excellent Governance award, MSCI ESG AA — the formal architecture is genuinely above-Korea-average.
• SK Inc. is paying its way (120% rights-issue allocation) and employees are oversubscribing the ESOP at 132% — both are real conviction signals.
• The new CEO transition (Kim Jong-woo) cleanly resolved the Park Won-cheol concurrent SKC/Absolics dual role that was a structural conflict.

Real concerns:

• ISS Compensation decile 8 + zero English per-officer pay disclosure means pay-for-performance during $805M of cumulative losses cannot be verified.
• 28-of-28 board resolutions approved in 2024 (and a similar pattern in prior years) reads as a board that endorses, not a board that pressures.
• Capital allocation has been one-way dilution: ~22% rights issue in 2026 + EB issuance + asset disposals, with no buyback or dividend.
• Parent SK Group sits behind every decision and faces its own governance overhang (Chairman Chey Tae-won's ~$1.0B divorce settlement remains under Supreme Court review and could force SK Group asset monetization).

The one thing that would change the grade:

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

How the Story Changed

For four years SKC told a single story: a legacy PET-film and chemicals business reinventing itself into a "Global ESG Material Solutions Company" centered on EV-battery copper foil, semiconductor test sockets and glass substrates, and biodegradable PBAT. The vision did not change. Almost everything else did. Capacity targets quietly faded. The "super-gap" language disappeared. By 2026 the framing was "stability, recovery, growth" — code that the prior plan had not worked. Three full years of operating losses, an asset firesale of ~$620M, a rights offering, and a CEO change have left credibility damaged but the strategic direction broadly intact.

1. The Narrative Arc

The story has compressed in ambition every year since 2022. The "Super-Gap" phrase the company used to describe its copper-foil lead has not appeared in earnings communications since 2023. References to a ~$15.8B corporate value target — a centerpiece of the 2022 sustainability report's silicon-anode pillar — were dropped entirely. The 2024 sustainability report swapped that vocabulary for the line "the EV market is entering a new phase," language that quietly accommodates SKC's 34% global copper-foil utilization.

2. What Management Emphasized — and Then Stopped Emphasizing

The cleaner read is a side-by-side: which themes faded, which arrived.

The most revealing fade is silicon anode. In 2022 SKC published a four-stage roadmap to mass-produce silicon-carbon composite anodes by 2026 with a 15% global share by 2032. The technology came from a 2021 consortium investment in Nexeon and was anchored to a ~$15.8B corporate-value target. By 2024 the topic was reduced to a passing reference. By 2025 it was gone. Management never explicitly cancelled the program; it just stopped talking about it.

3. Risk Evolution

The risk discussion in the formal sustainability reports stayed almost entirely on climate, governance, occupational safety, and supply-chain ESG — every year. The risks that actually moved the share price — EV-demand collapse, copper-foil utilisation, balance-sheet stress, goodwill impairment — appeared in earnings decks, not in risk-factor disclosure. The 2024 sustainability report's "Material Issue Selection Results" still ranked Climate Change Response, Waste/Pollutant Reduction, and Occupational Safety as top issues. By that point, equity had fallen by half and net debt was 2.4× equity. That is a genuine disconnect between formal risk disclosure and the risks shareholders bore.

The newer risks management began naming explicitly:

• Goodwill impairment. Q2 2024 quietly recognised ~$24M impairment on financial assets. Q4 2025 booked a ~$217M "other expense" line driving the ~$344M quarterly net loss — the largest single-quarter loss in the dataset.
• Tariff exposure. First mentioned 1Q25 (PG/SM US tariff impact), elevated through 2Q25, then de-emphasised by 4Q25 once chemicals turned a 1Q26 profit.
• Capital allocation strain. Net debt rose from ~$1.77B (FY22) to ~$1.92B (FY24); the ~$1.73B target announced in 3Q25 was missed at FY25 end (~$1.81B).

4. How They Handled Bad News

The pattern is consistent: management explained misses through external factors (EV slowdown, semiconductor downcycle, tariffs, KRW strength) and bracketed the disappointing numbers with forward-looking optimism ("recovery expected from Q2," "spread improvement underway," "milestones on track"). The framing was not dishonest — the EV demand shock was real — but the company rarely conceded that targets were stretched in the first place.

The most important wording change is the 2024 CEO letter, written for the FY2024 sustainability report. The phrase "not speed, but the right direction" is doing real work: it concedes that the 2022 expansion thesis was overheated, without retracting any specific target. It is honest in tone and evasive in substance.

5. Guidance Track Record

The dataset (eight quarterly decks plus four sustainability reports) yields ten distinct, valuation-relevant promises. Six were missed, three were delivered, and one was abandoned without explanation.

Why 4/10. Three things keep this from being lower: (a) the asset-divestment program was delivered roughly on schedule and roughly at the announced size — in distress that is not a given; (b) ISC and AI-socket guidance has been consistently met or beaten; (c) management never fabricated numbers or misled on the direction of trends — the misses were all out-in-the-open. Four reasons it is not higher: the silicon-anode and 250 kt targets were never formally retracted, so the walk-back was achieved by silence; the glass-substrate mass-production date has slipped at least two years with rolling new milestones; the net-debt target was missed within one quarter of being set; and the rights offering — a substantive equity dilution event — became necessary despite four years of language about "balance-sheet improvement" and "operational efficiency."

6. What the Story Is Now

The current story, post-CEO change, is "stability, recovery, growth" — a sequence that is honest about where the business sits. SKC is now a copper-foil + AI-test-socket + commodity-chemicals company with two early-stage growth options (glass substrate, PBAT) that have not yet delivered. The corporate identity is intact. The pace is not.

The Q1 FY2026 deck is the cleanest signal in the dataset. EBITDA turned positive (~$7M) for the first time since Q2 2023 — eleven quarters of negative EBITDA. The chemical segment swung to OP +~$6.5M after seven straight loss quarters. Semi material posted record OP. EV foil narrowed losses with NA volumes accelerating. None of this proves the business has turned, but it is the first quarter in three years where the data and the management language pointed in the same direction. That alignment is what the new CEO inherits.

Financials — What the Numbers Say

Figures converted from Korean Won at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

1. Financials in One Page

SKC is a $1.27 billion-revenue specialty-materials conglomerate that is half-finished with a strategic transformation from legacy chemicals/PET-film into copper foil for batteries (SK nexilis), semiconductor test sockets (ISC), and glass substrate (Absolics). The numbers tell a stark story: revenue has held flat around $1.15-1.27 billion since FY2023, but operating losses widened every year — from $-165 M (FY23) to $-188 M (FY24) to $-210 M (FY25), and net loss ballooned to $-496 M in FY25. EBITDA was negative for eleven straight quarters until Q1 FY2026 finally posted +$7 M — the first "signal flare" of recovery. The balance sheet is heavily levered: interest-bearing debt sits near $2.54 B against parent equity that has shrunk from $1.68 B (FY21) to $574 M (FY25) — a -66% erosion (compounded by KRW weakness). Liquidity tightened to a sub-1.0 current ratio in FY24, prompting an asset rebalancing programme of $616 M in 2025 plus a fresh rights offering listing 8 Jun 2026. At $108.7/share the market is paying ~7.3× book and ~3.3× sales for a company losing $-348 M in net cash NPV every twelve months. Consensus target sits at $72 (UNDERPERFORM, 9 analysts). The single financial metric that matters now is quarterly EBITDA trajectory: Q1 FY26's swing to positive must be sustained for two more quarters before the equity story has any underwriting basis.

How to read the scoring metrics in this report. SKC's financial data is published only via Korean DART filings; many third-party scoring metrics (Quality Score, Fair Value, Altman Z, Piotroski F, Beneish M) are not available in the data set. We rely on directly computed margins, leverage ratios, and segment economics throughout.

---

2. Revenue, Margins, and Earnings Power

SKC's reported revenue base has been completely reshaped twice. Industrial Materials (PET film) was divested in 2022; SK enpulse CMP/blank mask assets were divested in 2025. Continuing-operations restatements mean the revenue line below is comparable from FY2022 onward but apples-to-oranges versus FY20-21. We show the full series for context, then focus on FY22+.

What the chart actually says. FY2021 was a peak (PG/SM commodity-chemical super-cycle plus film business intact). The 2022 divestiture removed a large profit pool, and the new portfolio has not yet replaced the lost economics. Operating margin has held in the -14% to -17% band for three years — i.e., the loss is structural, not cyclical. Net margin is materially worse than operating margin (-39% in FY25) because of equity-method losses (mostly Absolics ramp-up) and goodwill/intangible write-downs.

Recent quarterly trajectory (the story that matters now)

What changed in Q1 FY2026. Revenue +13.4% YoY. Operating loss narrowed to $-19.5 M from $-74 M in 4Q25. Crucially, all three operating segments delivered better numbers: copper foil (SK nexilis) loss narrowed (Malaysia plant standalone EBITDA turned black), semi-test (ISC) put up record $46 M revenue at 35% OP margin, and chemicals (SK picglobal) flipped to a +$6.5 M operating profit on PG tightness. Q4 FY2025 was inflated by one-time write-downs, so 4Q-to-1Q reads larger than the underlying improvement — but the trend across all three legs is positive for the first time in two years.

---

3. Cash Flow and Earnings Quality

SKC does not publish a full cash-flow statement in its English disclosures (the audited statement is in the Korean DART business report). What we can observe directly is the end-of-period cash balance and EBITDA, which is enough to answer the most important question for any loss-making transformation story: Is the cash balance compatible with the burn rate?

Free cash flow = cash from operations minus capital expenditure. It is the cash a business actually keeps after running and reinvesting. For loss-making companies, FCF is what determines whether they survive without dilution.

The 2025 cash bounce is not from operations. End-FY2024 cash was $274 M; end-FY2025 cash was $721 M. EBITDA in FY2025 was $-79 M — i.e., operations consumed cash. The $+447 M cash gain was overwhelmingly financing plus asset rebalancing:

Source	Amount ($M)	Notes
CMP Pad divestiture	231	SK enpulse CMP-pad business sold
FCCL divestiture	66	Flexible copper-clad laminate
Exchangeable bond issuance	266	EB on ISC shares
Blank Mask divestiture	47	SK enpulse blank-mask business
CMP Slurry divestiture	8	SK enpulse slurry assets
Total 2025 asset rebalancing	616	Per company disclosure
Plus financing (rights offering announced)	TBC	New shares list 8 Jun 2026

Earnings quality verdict. Reported net income is materially worse than operating income — the gap is ~$280-300 M per year — driven by:

1. Equity-method losses from Absolics (glass substrate JV in Covington, GA): roughly $-50 to $-55 M/year of share of associate losses while it ramps.
2. Asset impairments on disposed and underperforming legacy assets.
3. Interest expense on ~$2.5 billion of gross debt: net non-operating items were $-273 M in FY25.
4. Non-controlling interest dynamics: Total net loss $-496 M vs parent share $-507 M — losses attributable to minorities are smaller than total losses, meaning the parent (and public shareholders) bear a disproportionate share of the consolidated red ink.

EBITDA is "less bad" than operating income because depreciation runs ~$130 M/year on a ~$2.2 billion tangible asset base. That depreciation is a real cash cost replacement for an asset-heavy commodity business — investors should not treat the gap as paper losses.

---

4. Balance Sheet and Financial Resilience

The balance-sheet question is binary: can SKC fund the next 18-24 months of cash burn while the transformation matures?

What the balance sheet shows.

• Parent equity has eroded by 66% in four years ($1,681 M → $574 M, exaggerated by KRW depreciation). Three more years of FY24-25-style losses would wipe it out.
• Total liabilities-to-assets has crept to 70% by FY25 vs 63% in FY21. The book is mechanically de-equitising.
• FY24 current ratio of 0.69 was the alarm bell — short-term liabilities of $1,503 M vs current assets of $1,034 M implied a refinancing requirement and triggered the 2025 asset-disposal programme.
• FY25 cash of $721 M looks healthy but is largely the recycled disposal proceeds and EB issuance; net debt is still ~$1,817 M.
• Goodwill + intangibles of $915 M (20% of assets) are concentrated in the ISC acquisition (2023, ~$1.0 B) and historical battery-materials goodwill — a future operating-loss driver if write-downs continue.

Refinancing/funding actions in the past 12 months:

1. 2025 asset rebalancing of $616 M (SK enpulse CMP/blank mask/slurry, FCCL, EB on ISC).
2. $220 M equity-equivalent funding from Korea Investment PE and others (announced May 2025).
3. $40 M IFC strategic investment in SK leaveo (PBAT, Vietnam).
4. $40 M CHIPS Act subsidy for Absolics glass-substrate plant (Covington, GA).
5. Rights offering announced Q1 FY2026; new shares listing 8 Jun 2026 (size unspecified in English disclosures — material-dilution risk).
6. Cancelled cathode-material investment plan in Dec 2025 — explicit capex discipline.

---

5. Returns, Reinvestment, and Capital Allocation

ROIC is meaningfully negative. With operating income of $-210 M and an invested capital base of roughly $4.1 billion (parent equity + interest-bearing debt - cash), pre-tax ROIC is ~-5%, against an estimated cost of capital of 8-10% for a Korean specialty-chemicals company. Per $1 of capital deployed, SKC is destroying $0.13-0.15 of value annually at current run-rate. This is the central financial fact about the business.

Capital allocation under the current management

Notes on the capital-allocation chart. Capex/acquisition figures are management-disclosed approximations from earnings-release narratives because the full English cash-flow statement is not published. Buybacks and dividends are zero on continuing operations: SKC stopped paying dividends in 2022 after the divestitures, and there are no buyback programmes announced.

Share-count dynamics. Common shares outstanding ≈ 37.9 M (₩189.3 bn capital stock at ₩5,000 par). With a rights offering scheduled to list 8 Jun 2026, share count is set to rise — quantum not yet disclosed in English filings; investors should expect 5-15% dilution as a working assumption pending the prospectus.

Capital-allocation verdict. Management's allocation pattern in 2025 is defensive, not offensive: divest non-core (CMP, blank mask, FCCL), issue exchangeable bonds (deferred dilution), prepare a rights offering. The single offensive bet — Absolics glass substrate, ~$1.6bn cumulative investment — has yet to generate revenue. This is the textbook pattern of a company financing a 5-7 year structural pivot rather than a value-compounder.

---

6. Segment and Unit Economics

The aggregate numbers hide one critical fact: only one of SKC's four segments is profitable.

Reading the segment economics

1. Chemical (SK picglobal) — 59% of revenue, structurally loss-making. PG/styrene monomer is a commodity-spread business in a chronic Asian-overcapacity downcycle. FY25 OP margin: -6.6%. Q1 FY26 saw a tiny +$6.5 M profit on PG tightness from Middle-East geopolitical disruption — likely transient. This is the legacy drag that the divestiture programme has not yet fixed.

2. EV battery material (SK nexilis copper foil) — 28% of revenue, $-121 M loss. Loss-making at -34% OP margin in FY25 due to under-utilisation in Korea/Malaysia/Poland plants while volumes ramp. Q1 FY26 showed encouraging signs: ESS-segment volumes +390% YoY, North-American volumes +403% YoY, Malaysia plant standalone EBITDA positive. This is the segment investors are paying for in the current valuation.

3. Semi material (ISC test sockets) — 12% of revenue, 27% OP margin, +$41 M profit**. The crown jewel. Acquired in 2023 for ~$1.0 B. AI/HBM tester demand drove +35% YoY revenue growth in FY25 with expanding margins on high-end SLT (System-Level-Test) socket mix. This is the only segment generating returns above cost of capital**. Management guides 20%+ revenue growth in 2026 with strategic capex in Vietnam.

4. New business (Absolics glass substrate + SK leaveo PBAT) — virtually no revenue, $-35 M loss. Pre-revenue, capital-consumptive. Absolics has a Covington, GA plant operational with $40M CHIPS Act support but qualification cycles for high-end semiconductor packaging are 18-36 months. PBAT plant in Vietnam now mechanically complete with $40M IFC investment.

---

7. Valuation and Market Expectations

Because SKC is loss-making, traditional P/E and EV/EBITDA are not meaningful. The valuation has to be read through price/sales and price/book plus a scenario analysis.

What the price implies

At $108.7, the market is paying 7.3× book on parent equity — a premium that requires belief that parent equity grows via Absolics commercialisation, ISC contribution, and SK nexilis turnaround, not that today's segment economics hold. On a P/S basis, 3.3× sales is at the top end of SKC's own 5-year range (1.5-3.3×).

Bear / Base / Bull scenario pegs (illustrative, USD)

Consensus signal. Per third-party aggregators: 9 sell-side analysts cover SKC with a mean UNDERPERFORM rating and an average 12-month target of $72 — implying -34% downside from spot. Nomura downgraded SKC to "Reduce" in April 2025 with target $61 (from $102). Stockopedia's consensus is $77. The bull case in the market is being expressed mostly through retail KOSPI flows rather than institutional underwriting.

---

8. Peer Financial Comparison

The Korean peer set spans copper-foil battery materials (Lotte Energy Materials, Solus Advanced Materials), semiconductor consumables (Hansol Chemical, LEENO Industrial), and basic chemicals (Lotte Chemical). Note: peer financial detail is partial — full reconciled three-year line items are pending in our dataset for several names.

Peer-comparison observation. SKC's EV/Sales of 3.3× sits above mature commodity peers (Lotte Chemical 0.6×, Solus 3.0×) and below the semi-test specialists (LEENO Industrial 21.9×, Hansol Chemical 3.6×). Read mechanically, SKC is being priced as if its future revenue mix will look more like Hansol Chemical / LEENO (semiconductor consumables/sockets) than Lotte Chemical / Solus (commodity battery materials). That premium is not unreasonable as a forward bet on the ISC + Absolics economics, but it bakes in successful execution.

LEENO Industrial — the closest pure-play comparable for ISC's test-socket business — trades at 39× EV/EBITDA. If ISC's standalone FY25 EBITDA is roughly $55 M (41 OP + ~14 D&A), implied standalone enterprise value at LEENO multiples ≈ $2.1 billion — i.e., ISC alone could justify ~50% of SKC's current market cap. That is the sum-of-the-parts argument supporting the current price. The other ~$3.8 billion of SKC EV must be carried by SK nexilis copper foil + chemicals + Absolics + balance-sheet deductions.

---

9. What to Watch in the Financials

Closing read on the financials

What the numbers confirm. SKC is mid-transformation, value-destroying at the consolidated level (-90% ROE on parent equity in FY25), but with a clearly identifiable profitable segment (ISC) and a credible defensive capital programme ($616 M 2025 disposals + rights offering). The Q1 FY2026 EBITDA inflection is the first hard data point that could validate the thesis.

What they contradict. The $721 M cash balance at FY25 looks reassuring on paper but cannot be read as operating strength — it is recycled disposal proceeds. The market's 7.3× P/B is inconsistent with three years of deepening losses unless one underwrites the SOTP optionality of ISC + Absolics.

The first financial metric to watch is the 2Q FY2026 EBITDA print — does the +$7 M turn into +$20-28 M or revert to negative? A second consecutive positive print would be the strongest confirmation that the structural losses are giving way to operating leverage; a reversion would refocus the market on the rights-offering quantum and on equity-cushion erosion.

---

Figures in this report are presented in US Dollars ($) at historical FX rates from data/company.json.fx_rates. SKC's full audited statements are filed in Korean on DART (Korea's electronic disclosure platform); English-language disclosures are limited to Sustainability Reports and quarterly earnings-release decks. Where cash-flow line items are unavailable in English, we have noted estimates derived from balance-sheet movements and management commentary. Ratios, margins, and multiples in this file are unitless and identical to the native-currency version.

Web Research — What the Internet Knows

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged. Global TAM and US-sourced figures (CHIPS Act grants, Toyota Tsusho investment) are already USD-denominated and shown as-is.

The Bottom Line from the Web

The single most important external signal the filings cannot show is timing slippage on the entire investment story: Absolics glass-substrate mass production has now slid from a 2022-promise of "2024" to a year-end-2026 target with no named hyperscaler customer disclosed, while the 250kt copper-foil "global No. 1 by 2025" plan never materialised. Yet the company is simultaneously running a ~$680M June-2026 rights offering (~60% earmarked for Absolics) into a depressed share price — a dilution that consensus rates Underperform / Neutral with target $69–77 per share versus spot $108.7. The bull-bear pivot for 2026 is the Q1 EBITDA inflection (first positive in 10 quarters) versus a Korean PTAB ruling in February 2026 that tilted the Solus copper-foil patent dispute against SK Nexilis.

What Matters Most

1. ~$680M rights offering closing June 8, 2026 — ~60% directed to Absolics

SKC announced on Feb 26, 2026 a ~$680M rights issue, with roughly $401M going to glass-substrate subsidiary Absolics and the balance to debt reduction; SK Inc. (40.6% holder) supports the issue and the new listing date is June 8, 2026 (TradingView ticker 0117901G). Independent analyst Douglas Kim modelled ~22% dilution at pre-Feb prices. This is by far the most material near-term capital event and explains the simultaneous CEO turnover.

2. CEO Kim Jong-woo replaces Park Won-cheol (March 26, 2026) — also takes SK Nexilis CEO seat

The 53rd AGM appointed Kim Jong-woo (ex-Intel and SK hynix engineer/strategist) as CEO under a "Stability, Recovery and Growth" mandate. Kim concurrently runs SK Nexilis; new CFO Park Dong-ju (ex-SK Inc. portfolio planning) is also dual-hatted as Nexilis CFO. Parent SK Inc. is visibly retaking financial control as the rights offering lands.

Sources: thelec.net/news/articleView.html?idxno=6127 · skc.kr/m/eng/Conmmunication/news/newsDetail.do?seq=1693

3. Glass-substrate mass production slips again — to year-end 2026

TrendForce (May 8, 2026) reports SKC is "speeding glass substrate mass production by year-end" — confirming the original 2022 promise of "mass production 2024" has slipped first to 2H-2025 and now to late-2026. Q3-2025 SKC release said "samples enter customer qualification process" and Phase-1 build at Covington, Georgia continues. Absolics has no publicly named hyperscaler customer (NVIDIA / AMD / Google) as of May 2026, though The Elec said in late 2025 Absolics is "close to AMD approval" and Chey Tae-won publicly suggested NVIDIA interest at CES 2025.

4. FY2025 reset — $210M operating loss, $218M Q4 impairment, $616M liquidity raise

Per SKC's Feb 5, 2026 release, FY2025 consolidated revenue was $1.27B with an operating loss of $210M; Q4 booked $218M in one-off impairments of tangible assets in the secondary-battery and chemical businesses. To shore up liquidity SKC raised $616M in 2025 via perpetual exchangeable bonds and asset securitisations of non-core businesses — a stress signal that pre-staged the 2026 rights issue.

5. Q1 2026 inflection — EBITDA positive for the first time in 10 quarters

April 27, 2026 release: revenue +13.4% YoY to $337.7M, operating loss narrowed to $19.5M, EBITDA turned positive at $6.8M and EPS beat consensus by 17.5%. Per the Q1 IR PDF, Q1 ESS-grade copper-foil sales volume rose +132% QoQ and +390% YoY; North-America-bound copper-foil volume +95% QoQ and +403% YoY. The technical setup matches: stock +35.5% YTD into May 8, 2026 close.

6. Solus Advanced Materials patent appeal upheld against SK Nexilis (Feb 2026)

Korea's IP Trial and Appeal Board upheld Solus Advanced Materials' copper-foil patent in February 2026, "tilting the dispute against SK Nexilis." The U.S. PTAB denied SK Nexilis's IPR institution; the parallel E.D. Texas trade-secret case (2:23-cv-00539) advances. This is a material overhang on copper-foil segment value not flagged in standard sell-side research.

7. Cathode investment plan cancelled (Dec 31, 2025) — strategic retreat

SKC formally cancelled a planned battery-cathode investment programme on the last trading day of 2025 — a notable retreat from earlier secondary-battery materials expansion ambitions and a precursor to the 2026 portfolio reorganisation around Absolics. Combined with the cancelled silicon-anode/Nexeon hand-off, the 2021 ambition of becoming "global No. 1 in copper foil by 2025 with 250kt output" has been quietly retired.

Sources: marketscreener.com/quote/stock/SKC-CO-LTD-6491661/news · pulsenews.co.kr/view.php?sc=30800028&year=2021&no=912500

8. Consensus is Neutral with target ~$69–77 vs ~$108.7 spot — implying ~30% downside

Stockopedia consensus target $76.72; Investing.com average $71.25; Yahoo: low $48.96 / avg $72.36 / high $95.20. Rating mix: 2 Buy / 5 Sell / 3 Hold from 10 actively-rating analysts of 25 covering. Nomura downgraded to Reduce on Apr 4, 2025, slashing target to $61.20 from $102.00. The street has not yet caught up to the Q1 inflection.

9. Absolics secured CHIPS Act $75M for Covington, GA glass-substrate facility

US Commerce Department awarded Absolics $75M in CHIPS-Act funding (May 29, 2024 announcement; first-phase released May 14, 2025) to support a 120,000-sq-ft glass-substrate plant backing ~$300M total Absolics investment. This is the only direct US-government endorsement of SKC's glass-substrate platform and an asymmetric upside if customer qualification lands.

10. Historic governance flag — Cho Dae-sik indictment (May 25, 2021) over SKC capital injections into SK Telesys

SK Group's #2 executive Cho Dae-sik (Chairman of SK Supex Council and former Chairman of SKC's BoD) was indicted for breach of trust over SKC's ~$60M (2015) and ~$18M (2012) capital injections into capital-eroded affiliate SK Telesys. Prosecutors said SKC "appeared to have skipped appropriate investment reviews ahead of its SK Telesys deals." Co-defendants included an ex-SKC senior exec and SK Telesys CEO (accounting fraud — inflated assets ~$13M). SK Chairman Chey Tae-won was an unindicted co-conspirator.

Recent News Timeline

What the Specialists Asked

Governance and People Signals

Ownership and Board

New CEO (appointed 2026-03-26): Kim Jong-woo

Key Governance Issues

Capital Raises and Insider Activity (2025–2026)

The 2025 cash-raising pattern — three private placements, one securitisation programme, one inbound JV equity from Toyota Tsusho — pre-stages the Feb-2026 ~$680M public rights issue. Cumulative non-organic financing in 2025 reached ~$1.17B versus a market cap of ~$4.38B as of May 8, 2026.

Industry Context

Copper foil price softness offsets volume gains

Two contradictions matter for the 2026 thesis. First, management talks "operational efficiency from full-scale Malaysia plant" and ~50% YoY secondary-battery sales growth, but Chinese copper-foil prices for lithium batteries softened into Feb 2026 with "intensified market divergence." Margin gains from utilisation may not flow through to the P&L if processing fees keep falling. Source: copperexpo.com.cn (Feb 2026).

Glass substrate — competitive window narrows in 2027

Samsung Electro-Mechanics publicly targets the $12B glass-substrate market with a 2027 ramp and is "in talks with Big Tech for supply" (Nov 2025). Intel licensing glass-substrate tech (TrendForce, Aug 2025) widens the field. Absolics's "world's first commercial" claim has a ~12-18 month window before Samsung enters with chaebol-scale capex behind it.

Semiconductor materials — a real bright spot

SKC's semiconductor materials segment hit highest-ever annual performance in 2025 from AI data-centre demand; high-growth products (CMP pads, etc.) jumped from 21% (2021) to 36% of semi-segment sales by 2025. ISC test-socket business benefits from a 7% CAGR market reaching $1.83B by 2030. Combined with Absolics, the semi-materials pillar is the highest-conviction part of the 2026 story.

Strategic portfolio rotation summary

Out: PET film business sold to Hahn & Co (~$1.26B, 2022); fine ceramics to Hahn & Co (~$266M, Feb 2024 — renamed Solmics); battery cathode plan cancelled (Dec 2025); silicon-anode role handed off to Nexeon (Dec 2025).

In: KCFT/SK Nexilis copper foil (~$1.10B, 2019/2020); 45% of ISC test sockets (~$402M, Jul 2023); Absolics glass substrate (multi-tranche capex, ~$300M total + ~$401M from 2026 rights raise); 17.23% of Ecovance (~$27.6M, Dec 2025).

The portfolio rotation is real and visible. Whether it creates value depends on execution at Absolics in the next 12-18 months and whether the copper-foil cycle stops eating equity.

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Where We Disagree With the Market

The variant view: the consensus mean target of $72 is not the operating-loss bear case it is sold as — the math only closes if ISC's KOSDAQ mark compresses roughly 25–30%, which no covering analyst has explicitly underwritten. SKC owns 45.03% of separately-listed ISC, worth ~$1.65B against SKC's $4.11B market cap; once you mark that piece daily, the residual implied value of nexilis + picglobal + Absolics + SK leaveo less parent net debt is only ~$1.08B at the consensus target — meaning either (a) consensus is implicitly pricing AI-multiple compression at ISC, or (b) the SOTP cannot be reconciled with the published targets. The market's stated debate is "rights-offering dilution + 1Q26 sustainability"; the actual decisive variable is ISC's daily standalone share price, which moves more SKC market cap per percentage point than any quarterly consolidated EBITDA print possibly can. We do not disagree that the stock is fully priced — we disagree about which observable signal resolves the debate, and we think the report's evidence base names that signal more honestly than any consensus note we found.

1. Variant Perception Scorecard

Reading the score. Consensus is unusually legible here — 9 sell-side analysts at mean UNDERPERFORM, $72 target, while spot is $109 and 30-day realised vol just printed 117%, the highest in a decade. That collision (uniformly bearish institutions, parabolic retail tape, ~22% rights dilution arriving 8 June) makes the positions easy to map. The variant strength is held below 70 because we agree with the bear's destination — we disagree with the bear's rationale. Resolution is short: the 8 June rights listing crystallises the dilution arithmetic; the 5 August 2Q26 EBITDA print rules on the operating inflection; ISC's daily KOSDAQ mark prints in the meantime. Four months is enough for all three to settle.

---

2. Consensus Map

The collision. The institutional bid is leaning on stale $61–72 targets; the tape is leaning on six-week +75% momentum; the company is days away from a ~22% share-count step-up. Each position implies a different model of the world. The variant view below sits inside that gap.

---

3. The Disagreement Ledger

Disagreement #1 — The decisive variable is ISC standalone, not 2Q26 EBITDA

A consensus analyst would say the August 5 consolidated EBITDA print resolves the SKC debate — does the +$6.8M 1Q swing hold or revert. The report's own SOTP arithmetic disagrees: ISC's KOSDAQ mark ($1.65B parent share, against SKC's $4.11B cap) moves more SKC market value per percentage-point shift than any plausible read of one quarterly EBITDA print. A 20% ISC compression strips ~$329M from SKC's stake — roughly 8% of cap — without SKC management doing anything, while the consolidated EBITDA print resolves at most a ~$20–54M operating swing. If we are right, the right thing for a PM to monitor first is KOSDAQ:095340 and the AI-capex revision wave at LEENO/Cohu, not the SKC investor-relations calendar. The cleanest disconfirming signal would be a 2Q26 EBITDA reversion to negative coinciding with ISC holding its mark within ±10% — i.e., the consolidated print does the work and the ISC mark does not.

Disagreement #2 — Consensus targets quietly require ISC to compress, but no analyst owns that view

A consensus analyst would say the $72 mean target reflects "operating losses, dilution, and below-cost-of-capital ROIC." The arithmetic does not survive that framing on its own. At $72 × ~37.9M pre-rights shares, market cap implied = $2.73B; minus the listed ISC stake at current KOSDAQ price of $1.65B leaves $1.08B for everything else. The SOTP residual — SK nexilis at replacement value, SK picglobal at trough peer multiples, Absolics + leaveo as options, less the parent net debt that sits outside ISC — does not credibly close to $1.08B unless ISC is also being marked down materially. The variant claim is that consensus targets are quietly an AI/HBM-multiple bet, not the operating bet they are framed as. If we are right, a PM short the stock on the operating thesis is also implicitly short the AI cycle through ISC — a position concentration that the published research has not made explicit. The cleanest disconfirming signal would be a covering analyst publishing an SKC note that explicitly flexes an ISC standalone scenario inside their target derivation; the cleanest confirming signal would be a sell-side downgrade arriving in lockstep with an ISC compression event, exposing the dependency.

Disagreement #3 — The "Q4 big-bath optical" critique does not touch the segment-level evidence

A consensus bear would say 1Q26 was flattered by the ~$218M 4Q25 impairment in EV battery + chemicals — i.e., the QoQ comparison is mechanically wider than the underlying improvement. That is true at the consolidated line. It does not, however, explain a Malaysia copper-foil plant turning standalone EBITDA-positive (a plant-level operating fact, not a consolidated impairment artifact), NA copper-foil volume +403% YoY, ESS volume +390% YoY, ISC +236% YoY operating profit at 35% margin, or chemicals swinging to +$6.5M operating profit first positive since 3Q22. Each of those is a segment- or plant-level print that the impairment wedge does not retroactively flatter. If we are right, 2Q26 EBITDA does not need to print +$20M to validate inflection — it needs ISC to hold its margin and any one of (chemicals, Malaysia, NA pull-through) to hold its 1Q gain. The cleanest disconfirming signal would be Malaysia plant standalone EBITDA flipping back negative and chemicals reverting to a loss in the same quarter, with no offsetting ISC strength; that combination would validate the "1Q was an artifact" reading.

---

4. Evidence That Changes the Odds

---

5. How This Gets Resolved

The cadence. ISC's daily mark prints continuously and dominates the SOTP arithmetic — it is the only signal that requires no waiting. The 8 June listing is the next hard date and resolves the dilution arithmetic, after which the $72 consensus target either becomes mechanically reachable or visibly stale. The 5 August 2Q26 print closes the inflection debate. Sell-side revisions and Absolics customer announcements are slower and lumpier — they do not need to happen for the variant view to be tested.

---

6. What Would Make Us Wrong

The cleanest break of this view is a single combination: 2Q26 EBITDA reverts to a clean negative print and ISC standalone holds its current $3.65B mark with no compression. That combination would say (a) the inflection thesis was an accounting/PG-spread artifact after all, and (b) the SOTP held together precisely because the AI multiple is more durable than we credited. The bears would have been right about the operating story, and consensus targets would close mechanically through dilution alone — making our claim that "consensus is quietly an AI-multiple bet" look like reverse-engineered cleverness rather than a real edge.

A more ordinary way we could be wrong is on the SOTP arithmetic itself. Our variant view treats consolidated parent net debt as a deduction against the ex-ISC residual, and treats the ISC stake as if the public can dispose of it at the KOSDAQ mark. Neither is fully clean. If parent net debt allocation shifts (the rights-offering proceeds split is $401M Absolics / $279M debt repayment) the ex-ISC residual changes; if the market applies a holding-company discount to the ISC mark inside SKC (which it almost certainly does), the implied "everything-else" residual is larger than the gross arithmetic suggests, and the consensus target stops requiring ISC compression to close. We have priced both adjustments inside our ranges, but a careful PM should test the ranges independently before committing to the variant.

There is also a quieter way we could be wrong: the consensus may be perfectly aware that its targets require ISC compression and simply not say so in published notes. Korean sell-side is famously opaque on cross-affiliate scenario analysis, and the absence of an explicit ISC scenario does not prove the analyst is unaware of it. If that is the case, the variant view loses its information value — it is true but already priced. The test is whether sell-side revisions over the next 60 days reference ISC standalone explicitly. If they do, the variant has been incorporated; if they continue to reference only consolidated EBITDA and rights-offering dilution, the gap is real.

The one piece of upstream evidence we are most exposed to is the forensic file's flag on the $410M FY25 below-the-line wedge. We have argued that the wedge applies to the consolidated comparison and not to the segment-level inflection prints. That is true if the wedge is mostly equity-method losses (Absolics) plus finance costs plus FX. If the K-IFRS Korean filings reveal that a meaningful portion of the wedge is segment-level write-downs that should have been allocated to operating engines, the segment-level prints we cite get smaller and the bear's "accounting artifact" critique becomes more credible. The disaggregation lives in DART Korean filings and we have not seen it.

The first thing to watch is the daily KOSDAQ price of ISC (095340) — every other resolving signal in this tab is downstream of it, and it is the only one printing today.

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Liquidity & Technical

SKC is institutionally tradable for mid-size funds, but execution risk is elevated — average daily volume of $77.6M supports 0.5–1% market-cap positions cleared in 2–5 days, while 2% positions need a full trading week. The tape is bullish on a 1–3 month horizon but flashes a volatility warning — price has rallied 75% in the last month, cleared the 200-day SMA by 49%, and is rising on accelerating volume, yet 30-day realized volatility just printed 117%, the highest in a decade. The most important tape feature is the rejection of the 2026-04-02 death cross by a parabolic move that has the 50d SMA about to re-cross above the 200d.

1. Portfolio implementation verdict

2. Price snapshot

3. The critical chart — 10-year price with 50/200 SMA

Price is 49.5% above the 200-day SMA. This is an uptrend, not a regime in transition.

The 10-year arc is a textbook three-act story: a slow base from 2016–2020 around $25–45, the EV-battery / SK-nexilis re-rating that took shares to an all-time high of roughly $190 in late 2021 (in then-prevailing FX), then a 60% drawdown into the 2024–2025 trough as net losses, copper-foil oversupply, and rising rates compressed the multiple. The current move is the strongest re-test of the post-2021 down-channel since the rally peaked.

4. Relative strength

5. Momentum — RSI and MACD

Momentum is positive but stretched. RSI(14) sits at 70 after a vertical move from sub-40 in early April; MACD histogram is at multi-quarter highs.

The two indicators tell a consistent story. RSI failures earlier in 2025 (overbought reversals at 73 in Jan-25 and 74 in Oct-25) preceded sharp drawdowns; the current 70 print is therefore a yellow flag for the 1–2 week window. But the MACD histogram has just made a new 18-month high ($3.86), and the line/signal spread ($9.67 vs $5.81) is widening, not narrowing — that is the signal you would want to see if the move has further to run. The bullish read holds; the warning is that adding here means accepting a non-trivial probability of a 5–10% pullback to $99–$102 in the very near term.

6. Volume, sponsorship, and volatility regime

Volume confirms the rally; volatility regime is at a 10-year extreme. The 20-day average daily share volume (828K) is 82% above the 60-day average (456K) — institutions are present, not just absent retail.

The current 117% realized vol is the highest in the 10-year history we have (10y bands: p20 = 31%, p50 = 40%, p80 = 59%). For comparison: the 2021-Q4 bubble peak printed 79%, the 2024-Q2 EV-battery rally peaked at 80%, and the 2025-Q1 squeeze top hit 88%. We are 33–48 points above any prior regime peak. This means a buy-and-hold position is being marked at vol levels typically associated with crisis-driven blow-offs, not orderly trends.

7. Institutional liquidity panel

This panel is for buy-side firms. The tape question is "is something happening?"; this section answers "can my fund trade it?"

A. ADV and turnover

ADV 20d is 82% above ADV 60d — recent volume is a regime acceleration, not a blip. Annual turnover of roughly 547% (5.5x float traded each year) places SKC firmly in the high-velocity quartile of Korean mid-caps; this is typical for a stock with a heavy retail base and an active EV-battery / glass-substrate thesis.

B. Fund-capacity table

Read this as: a fund of $1.8B AUM can build a 5% position by trading 20% of ADV for five sessions; cut participation in half (10% ADV) and the same 5% position is only viable for a $0.9B fund. A concentrated US/UK fund managing $4B+ should treat SKC as a 1–2% weight at most.

C. Liquidation runway

D. Execution friction

The 60-day median daily range is 4.21% — well above the 2% threshold for "low-friction" execution. Combined with 117% realized vol, this means even a passive 10%-ADV builder should expect 30–50 basis points of slippage per session in normal liquidity, more during squeeze episodes. The largest issuer-level position that clears in five trading days is 2.19% of market cap at 20% ADV and 1.09% at 10% ADV.

8. Technical scorecard and stance

Net technical score: +3.

Stance — tape regime is bullish on a 3-to-6 month horizon

The tape reads as a regime change, not a one-off bounce — price has cleared the 200-day SMA decisively, the 50d is about to re-cross above the 200d, MACD is at multi-quarter highs, and volume confirms. The fundamentals tab flagged FY2025 net losses and balance-sheet strain; price action diverges from that read, consistent with the market pricing ISC test-socket and Absolics glass-substrate optionality plus the SK enpulse divestiture ahead of the income statement turning. Largest execution risk: 117% realized vol and a 4.2% daily range mean any builder needs to scale over 3–5 weeks rather than days, and a 15–20% retracement to $92–$95 would be a normal pause within the bullish setup rather than its invalidation.

Bullish confirmation: a weekly close above $125 (52-week high). A close above this level on rising volume opens the prior 2021 all-time-high zone of $135–$141 as the next reference.

Bearish invalidation: a weekly close below $73 (200-day SMA). Re-entering the sub-200d regime would re-impose the 2024–2025 down-channel and re-engage the most recent death cross.

Liquidity is not the constraint for funds up to roughly $1.8B at a 5% position with 20% ADV participation; larger funds should treat this as 1–2% weight or watchlist-only. The binding constraint is volatility — any builder here needs to scale over 3–5 weeks, not all-in.